Deletion of the SOCS3 Gene in Liver Parenchymal Cells Promotes Hepatitis-Induced Hepatocarcinogenesis

Gastroenterology

Volumn 131, Issue 1, 2006, Pages 179-193

  Ogata, Hisanobu ^a,b   Kobayashi, Takashi ^a   Chinen, Takatoshi ^a   Takaki, Hiromi ^a   Sanada, Takahito ^a   Minoda, Yasumasa ^a   Koga, Keiko ^a   Takaesu, Giichi ^a   Maehara, Yoshihiko ^b   Iida, Mitsuo ^b   Yoshimura, Akihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CARCINOGEN; CONCANAVALIN A; CRE RECOMBINASE; CYCLIN D1; DIETHYLNITROSAMINE; GAMMA INTERFERON; MYC PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; VASCULOTROPIN;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MODEL; CANCER PATIENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENETIC ASSOCIATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; KNOCKOUT MOUSE; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER INJURY; LIVER PARENCHYMA; LIVER PROTECTION; LIVER TUMOR; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAMPLE; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

EID: 33745750797     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.04.025     Document Type: Article

References (52)

1. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., and Darnell Jr. J.E. Stat3 as an oncogene. Cell 98 (1999) 295-303
2. Frank D.A. STAT signaling in the pathogenesis and treatment of cancer. Mol Med 5 (1999) 432-456
3. Turkson J., Bowman T., Garcia R., Caldenhoven E., De Groot R.P., and Jove R. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol 18 (1998) 2545-2552
4. Bromberg J.F., Horvath C.M., Besser D., Lathem W.W., and Darnell Jr. J.E. Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 18 (1998) 2553-2558
5. Fukada T., Hibi M., Yamanaka Y., Takahashi-Tezuka M., Fujitani Y., Yamaguchi T., Nakajima K., and Hirano T. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130. involvement of STAT3 in anti-apoptosis. Immunity 5 (1996) 449-460
6. Puthier D., Bataille R., and Amiot M. IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol 29 (1999) 3945-3950
7. Karni R., Jove R., and Levitzki A. Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. Oncogene 18 (1999) 4654-4662
8. Ivanov V.N., Bhoumik A., Krasilnikov M., Raz R., Owen-Schaub L.B., Levy D., Horvath C.M., and Ronai Z. Cooperation between STAT3 and c-jun suppresses Fas transcription. Mol Cell 7 (2001) 517-528
9. Sinibaldi D., Wharton W., Turkson J., Bowman T., Pledger W.J., and Jove R. Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts. role of activated STAT3 signaling. Oncogene 19 (2000) 5419-5427
10. Kojima H., Nakajima K., and Hirano T. IL-6-inducible complexes on an IL-6 response element of the junB promoter contain Stat3 and 36 kDa CRE-like site binding protein(s). Oncogene 12 (1996) 547-554
11. Kiuchi N., Nakajima K., Ichiba M., Fukada T., Narimatsu M., Mizuno K., Hibi M., and Hirano T. STAT3 is required for the gp130-mediated full activation of the c-myc gene. J Exp Med 189 (1999) 63-73
12. Bowman T., Broome M.A., Sinibaldi D., Wharton W., Pledger W.J., Sedivy J.M., Irby R., Yeatman T., Courtneidge S.A., and Jove R. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci U S A 98 (2001) 7319-7324
13. Yang E., Lerner L., Besser D., and Darnell Jr. J.E. Independent and cooperative activation of chromosomal c-fos promoter by STAT3. J Biol Chem 278 (2003) 15794-15799
14. Sasaki A., Yasukawa H., Suzuki A., Kamizono S., Syoda T., Kinjyo I., Sasaki M., Johnston J.A., and Yoshimura A. Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as the SH2 domain. Genes Cells 4 (1999) 339-351
15. Sasaki A., Yasukawa H., Shouda T., Kitamura T., Dikic I., and Yoshimura A. CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J Biol Chem 275 (2000) 29338-29347
16. Kinjyo I., Hanada T., Inagaki-Ohara K., Mori H., Aki D., Ohishi M., Yoshida H., Kubo M., and Yoshimura A. SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity 17 (2002) 583-591
17. Croker B.A., Krebs D.L., Zhang J.G., Wormald S., Willson T.A., Stanley E.G., Robb L., Greenhalgh C.J., Forster I., Clausen B.E., Nicola N.A., Metcalf D., Hilton D.J., Roberts A.W., and Alexander W.S. SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 4 (2003) 540-545
18. Kimura A., Kinjyo I., Matsumura Y., Mori H., Mashima R., Harada M., Chien K.R., Yasukawa H., and Yoshimura A. SOCS3 is a physiological negative regulator for granulopoiesis and granulocyte colony-stimulating factor receptor signaling. J Biol Chem 279 (2004) 6905-6910
19. Mori H., Hanada R., Hanada T., Aki D., Mashima R., Nishinakamura H., Torisu T., Chien K.R., Yasukawa H., and Yoshimura A. Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. Nat Med 10 (2004) 739-743
20. Yasukawa H., Ohishi M., Mori H., Murakami M., Chinen T., Aki D., Hanada T., Takeda K., Akira S., Hoshijima M., Hirano T., Chien K.R., and Yoshimura A. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol 4 (2003) 551-556
21. Croker B.A., Metcalf D., Robb L., Wei W., Mifsud S., DiRago L., Cluse L.A., Sutherland K.D., Hartley L., Williams E., Zhang J.G., Hilton D.J., Nicola N.A., Alexander W.S., and Roberts A.W. SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis. Immunity 20 (2004) 153-165
22. Howard J.K., Cave B.J., Oksanen L.J., Tzameli I., Bjorbaek C., and Flier J.S. Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haploinsufficiency of Socs3. Nat Med 10 (2004) 734-738
23. Schmitz J., Weissenbach M., Haan S., Heinrich P.C., and Schaper F. SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J Biol Chem 275 (2000) 12848-12856
24. Nicholson S.E., De Souza D., Fabri L.J., Corbin J., Willson T.A., Zhang J.G., Silva A., Asimakis M., Farley A., Nash A.D., Metcalf D., Hilton D.J., Nicola N.A., and Baca M. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc Natl Acad Sci U S A 97 (2000) 6493-6498
25. Roberts A.W., Robb L., Rakar S., Hartley L., Cluse L., Nicola N.A., Metcalf D., Hilton D.J., and Alexander W.S. Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc Natl Acad Sci U S A 98 (2001) 9324-9329
26. Takahashi Y., Carpino N., Cross J.C., Torres M., Parganas E., and Ihle J.N. SOCS3. an essential regulator of LIF receptor signaling in trophoblast giant cell differentiation. EMBO J 22 (2003) 372-384
27. Howard J.K., Cave B.J., Oksanen L.J., Tzameli I., Bjorbaek C., and Flier J.S. Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haploinsufficiency of Socs3. Nat Med 10 (2004) 734-738
28. Croker B.A., Metcalf D., Robb L., Wei W., Mifsud S., DiRago L., Cluse L.A., Sutherland K.D., Hartley L., Williams E., Zhang J.G., Hilton D.J., Nicola N.A., Alexander W.S., and Roberts A.W. SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis. Immunity 20 (2004) 153-165
29. Robb L., Boyle K., Rakar S., Hartley L., Lochland J., Roberts A.W., Alexander W.S., and Metcalf D. Genetic reduction of embryonic leukemia-inhibitory factor production rescues placentation in SOCS3-null embryos but does not prevent inflammatory disease. Proc Natl Acad Sci U S A 102 (2005) 16333-16338
30. Postic C., and Magnuson M.A. DNA excision in liver by an albumin-Cre transgene occurs progressively with age. Genesis 26 (2000) 149-150
31. Yoshida T., Ogata H., Kamio M., Joo A., Shiraishi H., Tokunaga Y., Sata M., Nagai H., and Yoshimura A. SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis. J Exp Med 199 (2004) 1701-1707
32. Kenmochi K., Sugihara S., and Kojiro M. Relationship of histologic grade of hepatocellular carcinoma (HCC) to tumor size, and demonstration of tumor cells of multiple different grades in single small HCC. Liver 7 (1987) 18-26
33. Bissell D.M., Wang S.S., Jarnagin W.R., and Roll F.J. Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation. J Clin Invest 96 (1995) 447-455
34. Yoshida T., Hanada T., Tokuhisa T., Kosai K., Sata M., Kohara M., and Yoshimura A. Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J Exp Med 196 (2002) 641-653
35. Chida Y., Sudo N., Sonoda J., Sogawa H., and Kubo C. Electric foot shock stress-induced exacerbation of alpha-galactosylceramide-triggered apoptosis in mouse liver. Hepatology 39 (2004) 1131-1140
36. Nakagawa R., Nagafune I., Tazunoki Y., Ehara H., Tomura H., Iijima R., Motoki K., Kamishohara M., and Seki S. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice. J Immunol 166 (2001) 6578-6584
37. Matsuda M., Nakamoto Y., Suzuki S., Kurata T., and Kaneko S. Interferon-gamma-mediated hepatocarcinogenesis in mice treated with diethylnitrosamine. Lab Invest 85 (2005) 655-663
38. Niu G., Wright K.L., Huang M., Song L., Haura E., Turkson J., Zhang S., Wang T., Sinibaldi D., Coppola D., Heller R., Ellis L.M., Karras J., Bromberg J., Pardoll D., Jove R., and Yu H. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21 (2002) 2000-2008
39. Fiorucci S., Santucci L., Antonelli E., Distrutti E., Del Sero G., Morelli O., Romani L., Federici B., Del Soldato P., and Morelli A. NO-aspirin protects from T cell-mediated liver injury by inhibiting caspase-dependent processing of Th1-like cytokines. Gastroenterology 118 (2000) 404-421
40. Tiegs G., Hentschel J., and Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest 90 (1992) 196-203
41. Takeda K., Hayakawa Y., Van Kaer L., Matsuda H., Yagita H., and Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci U S A 97 (2000) 5498-5503
42. Hong F., Jaruga B., Kim W.H., Radaeva S., El-Assal O.N., Tian Z., Nguyen V.A., and Gao B. Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis. regulation by SOCS. J Clin Invest 110 (2002) 1503-1513
43. Kovalovich K., DeAngelis R.A., Li W., Furth E.E., Ciliberto G., and Taub R. Increased toxin-induced liver injury and fibrosis in interleukin-6-deficient mice. Hepatology 31 (2000) 149-159
44. Haura E.B., Turkson J., and Jove R. Mechanisms of disease. Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2 (2005) 315-324
45. Hodge D.R., Hurt E.M., and Farrar W.L. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 41 (2005) 2502-2512
46. Jenkins B.J., Grail D., Nheu T., Najdovska M., Wang B., Waring P., Inglese M., McLoughlin R.M., Jones S.A., Topley N., Baumann H., Judd L.M., Giraud A.S., Boussioutas A., Zhu H.J., and Ernst M. Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling. Nat Med 11 (2005) 845-852
47. Wang T., Niu G., Kortylewski M., Burdelya L., Shain K., Zhang S., Bhattacharya R., Gabrilovich D., Heller R., Coppola D., Dalton W., Jove R., Pardoll D., and Yu H. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10 (2004) 48-54
48. Alvarez J.V., Febbo P.G., Ramaswamy S., Loda M., Richardson A., and Frank D.A. Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res 65 (2005) 5054-5062
49. Yoshikawa H., Matsubara K., Qian G.S., Jackson P., Groopman J.D., Manning J.E., Harris C.C., and Herman J.G. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 28 (2001) 29-35
50. He B., You L., Uematsu K., Zang K., Xu Z., Lee A.Y., Costello J.F., McCormick F., and Jablons D.M. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A 100 (2003) 14133-14138
51. Niwa Y., Kanda H., Shikauchi Y., Saiura A., Matsubara K., Kitagawa T., Yamamoto J., Kubo T., and Yoshikawa H. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 24 (2005) 6406-6417
52. Weber A., Hengge U.R., Bardenheuer W., Tischoff I., Sommerer F., Markwarth A., Dietz A., Wittekind C., and Tannapfel A. SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene 24 (2005) 6699-6708